Dr Dick has 20 years of experience in mycobacteriology, antibacterial drug discovery and R&D program management. His research focuses on Tuberculosis (TB) and Non-Tuberculous Mycobacteria (NTM) infections. Dr Dick holds a Toh Chin Chye visiting professorship at the Department and manages the TB drug discovery project portfolio of the National University’s SPRINT-TB tuberculosis program which he co-founded with Drs Alex Matter and Nick Paton in 2014. Since 2017 he is Director of Antimicrobial Drug Discovery and Associate Professor at the Public Health Research Institute (PHRI) and the Department of Medicine, New Jersey Medical School, Rutgers University. Prior to his current appointments he served 5 years as Director of the BSL3 Core Facility and Associate Professor at the National University of Singapore. Before he joined the National University Dr Dick worked for eight years in the pharmaceutical industry where he established and led the TB disease area at the Novartis Institute for Tropical Diseases, Singapore. At Novartis Dr Dick was responsible for the discovery portfolio from target identification to preclinical development. Dr Dick completed his post-doctoral fellowship at the Institute of Molecular and Cell Biology in Singapore, where he became principal investigator heading the Mycobacterium Biology Laboratory. He studied biochemistry, genetics and microbiology at the University of Heidelberg where he obtained his PhD in molecular bacteriology.
Prof Mike Kemeny's research is in Immune Inflammatory Diseases, Allergy and has published extensively in international journals. Prior to his appointment as Visiting Professor, Prof Kemeny was a staff member, having served 11 years with the Department.
Prof Ng's research is in Virology and has published extensively in international journals. Prior to her appointment as Visiting Professor, Prof Ng was a staff member, having served 32 years with the Department.
Prof Toshifumi Matsuyama received his PhD in Virology from Yamaguchi University, Japan. He performed his post-doctoral research in Ontario Cancer Institute. Prof Matsuyama has dedicated many years to interferon (IFN) as well as tumor necrosis factor (TNF) research. He identified for the first time that TNF activates NF-kappaB. He also cloned Interferon Regulatory factor 4 (IRF4), a molecule indispensable for the development of subsets of T cells, B cells, and dendritic cells. Prof Matsuyama was formerly the Dean of the School of Medicine at Nagasaki University (2009-2013).
Prof Ehud Razin received his B.Sc in Biology and M.Sc in Microbiology from the Hebrew University and his PhD in Immunology from the WIS. He performed his post-doctoral research in Sloan Kettering and Harvard University. Prof Razin has for many years been a major contributor and leading scientist in the field of mast cell biology. He was formerly the Dean of the Faculty of Medicine (2005-2009).
Dr Hanski received his PhD in 1979 in biochemistry from HUJ. He is currently a professor in the Dept of Clinical Microbiology at the Institute of Microbiology. In 2003, he received a Sarov award for excellent achievements in medical microbiology and in 1997, was made an honorary fellow of the Israeli MOS. For his scientific achievements he was nominated by The Howard Hughes Medical Institute as an International Scholar in Infectious Diseases.
Prof Pines received his BSc and PhD degree in Microbiology (1984) from Tel Aviv University. He served as the Head of the Department of Molecular Biology up until 2007. He is now an Associate Professor of Molecular Biology at the Hebrew University of Jerusalem. His research interests include Targeting, translocation across membranes, folding and subcellular distribution of proteins in yeast as a model for eukaryotic cells.
Prof Engelberg received his PhD in 1991 in Biological Chemistry from HUJ. He is currently an Assoc professor from the Dept of Biological Chemistry. He founded Jexys Pharmaceuticals which recently has signed a strategic research and development agreement with Teva Pharmaceuticals Industries Ltd. The company developed a unique high throughput drug discovery platform in yeas
Dr Friedlander is a Professor in Genetic-Epidemiology at the Hebrew University – Hadassah School of Public Health. He received his PhD degree in Genetic Epidemiology in 1985 from the Hebrew University. Between 1996 and 1999 he served as the Director of the Hebrew-University School of Public Health. In 2003, Dr Friedlander was appointed as the incumbent of the Jerrold M. Michael Chair in Public Health at the Hebrew University Faculty of Medicine.